Candel jumps on positive mid-stage trial data for lung cancer treatment

Candel Therapeutics

24/05/2024 11:14

** Shares of therapy developer Candel Therapeutics  CADL.O 
rise ~21.3% to $12.97 premarket
    ** CADL's therapy CAN-2409 in combination with valacyclovir
showed median overall survival of 20.6 months in patients with
non-small cell lung cancer (NSCLC)
    ** NSCLC is the most common type of lung cancer, and kills
more people in the United States than any other form of cancer,
according to the CDC
    ** Up to last close, stock up more than seven-fold YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))